Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

324 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.
Vollebergh MA, Lips EH, Nederlof PM, Wessels LFA, Schmidt MK, van Beers EH, Cornelissen S, Holtkamp M, Froklage FE, de Vries EGE, Schrama JG, Wesseling J, van de Vijver MJ, van Tinteren H, de Bruin M, Hauptmann M, Rodenhuis S, Linn SC. Vollebergh MA, et al. Among authors: van de vijver mj, van beers eh, van tinteren h. Ann Oncol. 2011 Jul;22(7):1561-1570. doi: 10.1093/annonc/mdq624. Epub 2010 Dec 6. Ann Oncol. 2011. PMID: 21135055 Free PMC article. Clinical Trial.
The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer.
Straver ME, Glas AM, Hannemann J, Wesseling J, van de Vijver MJ, Rutgers EJ, Vrancken Peeters MJ, van Tinteren H, Van't Veer LJ, Rodenhuis S. Straver ME, et al. Among authors: van t veer lj, van de vijver mj, van tinteren h. Breast Cancer Res Treat. 2010 Feb;119(3):551-8. doi: 10.1007/s10549-009-0333-1. Epub 2009 Feb 13. Breast Cancer Res Treat. 2010. PMID: 19214742
A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
Schouten PC, Dackus GM, Marchetti S, van Tinteren H, Sonke GS, Schellens JH, Linn SC. Schouten PC, et al. Among authors: van tinteren h. Trials. 2016 Jun 21;17(1):293. doi: 10.1186/s13063-016-1423-0. Trials. 2016. PMID: 27323902 Free PMC article. Clinical Trial.
Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.
Gross E, van Tinteren H, Li Z, Raab S, Meul C, Avril S, Laddach N, Aubele M, Propping C, Gkazepis A, Schmitt M, Meindl A, Nederlof PM, Kiechle M, Lips EH. Gross E, et al. Among authors: van tinteren h. BMC Cancer. 2016 Oct 19;16(1):811. doi: 10.1186/s12885-016-2848-2. BMC Cancer. 2016. PMID: 27756336 Free PMC article.
Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
de Boo L, Cimino-Mathews A, Lubeck Y, Daletzakis A, Opdam M, Sanders J, Hooijberg E, van Rossum A, Loncova Z, Rieder D, Trajanoski Z, Vollebergh M, Sobral-Leite M, van de Vijver K, Broeks A, van der Wiel R, van Tinteren H, Linn S, Horlings HM, Kok M. de Boo L, et al. Among authors: van der wiel r, van rossum a, van de vijver k, van tinteren h. Eur J Cancer. 2020 Mar;127:240-250. doi: 10.1016/j.ejca.2019.12.003. Epub 2020 Jan 16. Eur J Cancer. 2020. PMID: 31956037 Clinical Trial.
Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement.
Faneyte IF, Peterse JL, Van Tinteren H, Pronk C, Bontenbal M, Beex LV, van der Wall E, Richel DJ, Nooij MA, Voest EE, Hupperets P, Ten Vergert EM, de Vries EG, Rodenhuis S, van de Vijver MJ. Faneyte IF, et al. Among authors: van der wall e, van de vijver mj, van tinteren h. Clin Cancer Res. 2004 Jul 1;10(13):4457-63. doi: 10.1158/1078-0432.CCR-03-0054. Clin Cancer Res. 2004. PMID: 15240537 Clinical Trial.
A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial.
Drooger JC, van Tinteren H, de Groot SM, Ten Tije AJ, de Graaf H, Portielje JE, Jager A, Honkoop A, Linn SC, Kroep JR, Erdkamp FL, Hamberg P, Imholz AL, van Rossum-Schornagel QC, Heijns JB, van Leeuwen-Stok AE, Sleijfer S. Drooger JC, et al. Among authors: van tinteren h, van rossum schornagel qc, van leeuwen stok ae. Cancer. 2016 Oct;122(19):2961-70. doi: 10.1002/cncr.30141. Epub 2016 Jun 17. Cancer. 2016. PMID: 27315546 Free article. Clinical Trial.
High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.
Rodenhuis S, Bontenbal M, Beex LV, Wagstaff J, Richel DJ, Nooij MA, Voest EE, Hupperets P, van Tinteren H, Peterse HL, TenVergert EM, de Vries EG; Netherlands Working Party on Autologous Transplantation in Solid Tumors. Rodenhuis S, et al. Among authors: van tinteren h. N Engl J Med. 2003 Jul 3;349(1):7-16. doi: 10.1056/NEJMoa022794. N Engl J Med. 2003. PMID: 12840087 Free article. Clinical Trial.
Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy.
Hannemann J, Kristel P, van Tinteren H, Bontenbal M, van Hoesel QG, Smit WM, Nooij MA, Voest EE, van der Wall E, Hupperets P, de Vries EG, Rodenhuis S, van de Vijver MJ. Hannemann J, et al. Among authors: van hoesel qg, van der wall e, van de vijver mj, van tinteren h. Br J Cancer. 2006 Nov 20;95(10):1334-41. doi: 10.1038/sj.bjc.6603449. Epub 2006 Oct 31. Br J Cancer. 2006. PMID: 17088909 Free PMC article. Clinical Trial.
324 results